

**TOXICOLOGICAL PROFILE FOR  
N-NITROSODIPHENYLAMINE**

**U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES  
Public Health Service  
Agency for Toxic Substances and Disease Registry**

April 1993

## **DISCLAIMER**

The use of company or product name(s) is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry.

## UPDATE STATEMENT

A Toxicological Profile for *N*-nitrosodiphenylamine was released on December 1988. This edition supersedes any previously released draft or final profile.

Toxicological profiles are revised and republished as necessary, but no less than once every three years. For information regarding the update status of previously released profiles, contact ATSDR at:

Agency for Toxic Substances and Disease Registry  
Division of Toxicology/Toxicology Information Branch  
1600 Clifton Road NE, E-29  
Atlanta, Georgia 30333



## FOREWORD

The Superfund Amendments and Reauthorization Act (SARA) of 1986 (Public Law 99-499) extended and amended the Comprehensive Environmental Response, Compensation, and Liability Act of 1980 (CERCLA or Superfund). This public law directed the Agency for Toxic Substances and Disease Registry (ATSDR) to prepare toxicological profiles for hazardous substances which are most commonly found at facilities on the CERCLA National Priorities List and which pose the most significant potential threat to human health, as determined by ATSDR and the Environmental Protection Agency (EPA). The lists of the 250 most significant hazardous substances were published in the Federal Register on April 17, 1987, on October 20, 1988, on October 26, 1989, on October 17, 1990, and on October 17, 1991. A revised list of 275 substances was published on October 28, 1992.

Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the lists. Each profile must include the following:

- (A) The examination, summary, and interpretation of available toxicological information and epidemiological evaluations on a hazardous substance in order to ascertain the levels of significant human exposure for the substance and the associated acute, subacute, and chronic health effects.
- (B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure which present a significant risk to human health of acute, subacute, and chronic health effects.
- (C) Where appropriate, identification of toxicological testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

This toxicological profile is prepared in accordance with guidelines developed by ATSDR and EPA. The original guidelines were published in the Federal Register on April 17, 1987. Each profile will be revised and republished as necessary.


The ATSDR toxicological profile is intended to characterize succinctly the toxicological and adverse health effects information for the hazardous substance being described. Each profile identifies and reviews the key literature (that has been peer-reviewed) that describes a hazardous substance's toxicological properties. Other pertinent literature is also presented but described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

Each toxicological profile begins with a public health statement, which describes in nontechnical language a substance's relevant toxicological properties. Following the public health statement is information concerning levels of significant human exposure and, where known, significant health effects. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to protection of public health will be identified by ATSDR and EPA. The focus of the profiles is on health and toxicological information; therefore, we have included this information in the beginning of the document.

**Foreword**

The principal audiences for the toxicological profiles are health professionals at the federal, state, and local levels, interested private sector organizations and groups, and members of the public.

This profile reflects our assessment of all relevant toxicological testing and information that has been peer reviewed. It has been reviewed by scientists from ATSDR, the Centers for Disease Control and Prevention (CDC), and other federal agencies. It has also been reviewed by a panel of nongovernment peer reviewers and is being made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.

A handwritten signature in black ink, appearing to read "William L. Roper", with a stylized flourish at the end.

William L. Roper, M.D., M.P.H.  
Administrator  
Agency for Toxic Substances and  
Disease Registry

## **CONTRIBUTORS**

### **CHEMICAL MANAGER(S)/AUTHORS(S):**

Cassandra Smith-Simon, M.S.  
ATSDR, Division of Toxicology, Atlanta, GA

Lynne Haber, Ph.D.  
Clement International Corporation, Fairfax, VA

Elizabeth A. Kearns, Ph.D.  
Clement International Corporation, Fairfax, VA

### **THE PROFILE HAS UNDERGONE THE FOLLOWING ATSDR INTERNAL REVIEWS:**

1. Green Border Review. Green Border review assures the consistency with ATSDR policy.
2. Health Effects Review. The Health Effects Review Committee examines the health effects chapter of each profile for consistency and accuracy in interpreting health effects and classifying endpoints.
3. Minimal Risk Level Review. The Minimal Risk Level Workgroup considers issues relevant to substance-specific minimal risk levels (MRLs), reviews the health effects database of each profile, and makes recommendations for derivation of MRLs.
4. Quality Assurance Review. The Quality Assurance Branch assures that consistency across profiles is maintained, identifies any significant problems in format or content, and establishes that Guidance has been followed.





## CONTENTS

FOREWORD .....	v
CONTRIBUTORS .....	vii
LIST OF FIGURES .....	xiii
LIST OF TABLES .....	xv
1. PUBLIC HEALTH STATEMENT .....	1
1.1 WHAT IS <i>N</i> -NITROSODIPHENYLAMINE? .....	1
1.2 WHAT HAPPENS TO <i>N</i> -NITROSODIPHENYLAMINE WHEN IT ENTERS THE ENVIRONMENT? .....	2
1.3 HOW MIGHT I BE EXPOSED TO <i>N</i> -NITROSODIPHENYLAMINE? .....	2
1.4 HOW CAN <i>N</i> -NITROSODIPHENYLAMINE ENTER AND LEAVE MY BODY? ....	2
1.5 HOW CAN <i>N</i> -NITROSODIPHENYLAMINE AFFECT MY HEALTH? .....	3
1.6 IS THERE A MEDICAL TEST TO DETERMINE WHETHER I HAVE BEEN EXPOSED TO <i>N</i> -NITROSODIPHENYLAMINE? .....	3
1.7 WHAT RECOMMENDATIONS HAS THE FEDERAL GOVERNMENT MADE TO PROTECT HUMAN HEALTH? .....	4
1.8 WHERE CAN I GET MORE INFORMATION? .....	4
2. HEALTH EFFECTS .....	5
2.1 INTRODUCTION .....	5
2.2 DISCUSSION OF HEALTH EFFECTS BY ROUTE OF EXPOSURE .....	5
2.2.1 Inhalation Exposure .....	6
2.2.1.1 Death .....	6
2.2.1.2 Systemic Effects .....	6
2.2.1.3 Immunological Effects .....	6
2.2.1.4 Neurological Effects .....	6
2.2.1.5 Developmental Effects .....	7
2.2.1.6 Reproductive Effects .....	7
2.2.1.7 Genotoxic Effects .....	7
2.2.1.8 Cancer .....	7
2.2.2 Oral Exposure .....	7
2.2.2.1 Death .....	7
2.2.2.2 Systemic Effects .....	8
2.2.2.3 Immunological Effects .....	15
2.2.2.4 Neurological Effects .....	16
2.2.2.5 Developmental Effects .....	16
2.2.2.6 Reproductive Effects .....	16
2.2.2.7 Genotoxic Effects .....	16
2.2.2.8 Cancer .....	16
2.2.3 Dermal Exposure .....	18
2.2.3.1 Death .....	18
2.2.3.2 Systemic Effects .....	18
2.2.3.3 Immunological Effects .....	18
2.2.3.4 Neurological Effects .....	18
2.2.3.5 Developmental Effects .....	18

2.2.3.6	Reproductive Effects	18
2.2.3.7	Genotoxic Effects	18
2.2.3.8	Cancer	18
2.3	TOXICOKINETICS	19
2.3.1	Absorption	19
2.3.1.1	Inhalation Exposure	19
2.3.1.2	Oral Exposure	19
2.3.1.3	Dermal Exposure	19
2.3.2	Distribution	19
2.3.2.1	Inhalation Exposure	19
2.3.2.2	Oral Exposure	19
2.3.2.3	Dermal Exposure	19
2.3.3	Metabolism	20
2.3.3.1	Inhalation Exposure	20
2.3.3.2	Oral Exposure	20
2.3.3.3	Dermal Exposure	20
2.3.4	Excretion	22
2.3.4.1	Inhalation Exposure	22
2.3.4.2	Oral Exposure	22
2.3.4.3	Dermal Exposure	22
2.3.4.4	Other Routes of Exposure	22
2.4	RELEVANCE TO PUBLIC HEALTH	22
2.5	BIOMARKERS OF EXPOSURE AND EFFECT	30
2.5.1	Biomarkers Used to Identify or Quantify Exposure to <i>N</i> -Nitrosodiphenylamine	31
2.5.2	Biomarkers Used to Characterize Effects Caused by <i>N</i> -Nitrosodiphenylamine	31
2.6	INTERACTIONS WITH OTHER CHEMICALS	31
2.7	POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE	32
2.8	METHODS FOR REDUCING TOXIC EFFECTS	32
2.8.1	Reducing Peak Absorption Following Exposure	32
2.8.2	Reducing Body Burden	33
2.8.3	Interfering with the Mechanism of Action for Toxic Effects	33
2.9	ADEQUACY OF THE DATABASE	33
2.9.1	Existing Information on Health Effects of <i>N</i> -Nitrosodiphenylamine	34
2.9.2	Identification of Data Needs	34
2.9.3	On-going Studies	38
3.	CHEMICAL AND PHYSICAL INFORMATION	39
3.1	CHEMICAL IDENTITY	39
3.2	PHYSICAL AND CHEMICAL PROPERTIES	39
4.	PRODUCTION, IMPORT, USE, AND DISPOSAL	43
4.1	PRODUCTION	43
4.2	IMPORT/EXPORT	43
4.3	USE	43
4.4	DISPOSAL	43
5.	POTENTIAL FOR HUMAN EXPOSURE	47
5.1	OVERVIEW	47
5.2	RELEASES TO THE ENVIRONMENT	47

5.2.1	Air .....	47
5.2.2	Water .....	47
5.2.3	Soil .....	50
5.3	ENVIRONMENTAL FATE .....	50
5.3.1	Transport and Partitioning .....	50
5.3.2	Transformation and Degradation .....	50
5.3.2.1	Air .....	50
5.3.2.2	Water .....	51
5.3.2.3	Soil .....	51
5.4	LEVELS MONITORED OR ESTIMATED IN THE ENVIRONMENT .....	51
5.4.1	Air .....	51
5.4.2	Water .....	51
5.4.3	Soil .....	51
5.4.4	Other Environmental Media .....	51
5.5	GENERAL POPULATION AND OCCUPATIONAL EXPOSURE .....	52
5.6	POPULATIONS WITH POTENTIALLY HIGH EXPOSURES .....	52
5.7	ADEQUACY OF THE DATABASE .....	52
5.7.1	Identification of Data Needs .....	53
5.7.2	On-going Studies .....	54
6.	ANALYTICAL METHODS .....	55
6.1	BIOLOGICAL MATERIALS .....	55
6.2	ENVIRONMENTAL SAMPLES .....	55
6.3	ADEQUACY OF THE DATABASE .....	58
6.3.1	Identification of Data Needs .....	58
6.3.2	On-going Studies .....	59
7.	REGULATIONS AND ADVISORIES .....	61
8.	REFERENCES .....	65
9.	GLOSSARY .....	81
APPENDICES		
A.	USER'S GUIDE .....	A-1
B.	ACRONYMS, ABBREVIATIONS, AND SYMBOLS .....	B-1
C.	PEER REVIEW .....	C-1



**LIST OF FIGURES**

2-1	Levels of Significant Exposure to <i>N</i> -Nitrosodiphenylamine - Oral . . . . .	12
2-2	Metabolic Scheme for <i>N</i> -Nitrosodiphenylamine . . . . .	21
2-3	Existing Information on Health Effects of <i>N</i> -Nitrosodiphenylamine . . . . .	35
5-1	Frequency of NPL Sites with <i>N</i> -Nitrosodiphenylamine Contamination . . . . .	48



## LIST OF TABLES

2-1	Levels of Significant Exposure to <i>N</i> -Nitrosodiphenylamine - Oral . . . . .	9
2-2	Genotoxicity of <i>N</i> -Nitrosodiphenylamine <u>In Vitro</u> . . . . .	26
2-3	Genotoxicity of <i>N</i> -Nitrosodiphenylamine <u>In Vivo</u> . . . . .	29
3-1	Chemical Identity of <i>N</i> -Nitrosodiphenylamine . . . . .	40
3-2	Physical and Chemical Properties of <i>N</i> -Nitrosodiphenylamine . . . . .	41
4-1	Facilities That Manufacture or Process <i>N</i> -Nitrosodiphenylamine . . . . .	45
5-1	Releases to the Environment From Facilities That Manufacture or Process <i>N</i> -Nitrosodiphenylamine . . . . .	49
6-1	Analytical Methods for Determining <i>N</i> -Nitrosodiphenylamine in Biological Materials . . . . .	56
6-2	Analytical Methods for Determining <i>N</i> -Nitrosodiphenylamine in Environmental Samples . . . . .	57
7-1	Regulations and Guidelines Applicable to <i>N</i> -Nitrosodiphenylamine . . . . .	62

